UPyTher, a start-up pioneering innovative therapies for the treatment of patients with peritoneal cancer, has received funding from a group of investors. So far, peritoneal cancer often leads to unsuccessful treatments and increased mortality in patients with colon, ovarian, and gastric cancer.
The amount of the investment has not been disclosed. According to the start-up, the investment enables the preclinical development of UPyTher’s main product, UPT-211, for the treatment of peritoneal metastases of colon cancer. The company is now preparing the first clinical studies.
UPyTher B.V. is a spinout from the Eindhoven University of Technology dedicated to transforming peritoneal cancer into a treatable disease. UPyTher builds on patented polymer technology and pioneers innovative therapies specifically designed and developed for use in the abdominal cavity. UPyTher aims with a chemo-gel for a new standard in intraperitoneal therapy that provides life-saving possibilities for patients and makes intraperitoneal therapy simple, safe, and effective.
“Combined with the recently awarded OPZuid funding, this investment will accelerate the preclinical development program for UPT-211,” says CEO Geert van Almen. “This funding allows us to demonstrate the effectiveness and safety of our patented technology. It can serve as a platform for the development of a broad portfolio of innovative and effective therapeutics for the treatment of peritoneal cancer from other primary cancers such as ovarian and gastric cancer, as well as multiple other conditions in the abdominal cavity,” adds CTO Peter Paul Fransen.
Floris Hamel, Investment Manager at BOM, is convinced that UPyTher has the potential with its products to truly improve the lives of patients diagnosed with peritoneal cancer. “This start-up can change the current treatment paradigm by making intraperitoneal therapy simple, safe, and effective.”
UPyTher B.V. was founded in 2020 by Professor Patricia Dankers (pictured), Dr. Peter-Paul Fransen, and Dr. Geert van Almen as a spin-off from the DankersLab research group at Eindhoven University of Technology.
Article by Innovation Origins.
Learn more
